BCL2 and Decreased total neutrophil count: In one trial, ≥ Grade 3 neutropenia occurred in 42% of patients treated with the BCL‐2 inhibitor venetoclax (VEN) in combination with azacitidine versus 28% of those who received azacitidine and placebo [27].